anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In cases where the pulp exposure was more than 2 mm, the pulpotomy technique was employed. The procedure began with the removal of the pulp roof using steel round burs. The pulp was then amputated up to the pulp canal openings with a sterile sharp spoon excavator. Hemostasis was achieved using a sterile cotton pellet impregnated with physiological saline for 3-5 minutes. If hemostasis could not be achieved and inflammation had progressed to the root pulp, regenerative endodontics was applied. Once hemostasis was secured, the cavity was disinfected again with 2.5% sodium hypochlorite. A 2 mm thick layer of MTA was applied to the pulp base and covered with MTA resin-modified glass ionomer cement. The cavity walls were roughened with 35% orthophosphoric acid after removing material residues with a steel round bur. Following the application of a dentin bonding agent, the upper restoration was completed with composite resin using the layering technique.
The present disclosure relates to a vehicle, an information processing system, a recording medium, and an information processing method that enable a person to embrace a mood for confirming a health state. A vehicle (10) has an input unit (20), an output unit (21), and a control unit (22). The input unit (20) can detect a user input in the passenger space. The output unit (21) can notify information in the passenger space. The control unit (22) notifies a question for inquiry via the output unit (21). The control unit (22) notifies the build statement based on the answer to the question detected via the input unit (20).
Clevidipine is rapidly distributed and metabolized resulting in a very short half life. The arterial blood concentration of clevidipine declines in a multi-phasic pattern following termination of the infusion. The initial phase half-life is approximately 1 minute, and accounts for 85-90% of clevidipine elimination. The terminal half-life is approximately 15 minutes.

Distribution: Clevidipine is >99.5% bound to proteins in plasma at 37°C. The steady-state volume of distribution was determined to be 0.17 L/kg in arterial blood.

Metabolism and Elimination: Clevidipine is rapidly metabolized by hydrolysis of the ester linkage, primarily by esterases in the blood and extravascular tissues, making its elimination unlikely to be affected by hepatic or renal dysfunction. The primary metabolites are the carboxylic acid metabolite and formaldehyde formed by hydrolysis of the ester group. The carboxylic acid metabolite is inactive as an antihypertensive. This metabolite is further metabolized by glucuronidation or oxidation to the corresponding pyridine derivative. The clearance of the primary dihydropyridine metabolite is 0.03 L/h/kg and the terminal half-life is approximately 9 hours.

In vitro studies show that clevidipine and its metabolite at the concentrations achieved in clinical practice will not inhibit or induce any CYP enzyme.

In a clinical study with radiolabeled clevidipine, 83% of the drug was excreted in urine and feces. The major fraction, 63-74% is excreted in the urine, 7-22% in the feces. More than 90% of the recovered radioactivity is excreted within the first 72 hours of collection.
The invention belongs to the technical field of liver diseases, and particularly relates to shRNA and cDNA of a group of target regulation alpha-fetoprotein (AFP) genes and application thereof. The invention provides shRNA and cDNA of a liver-targeted regulation and control alpha fetoprotein gene and application thereof. The recombinant vector based on the shRNA can silence the alpha fetoprotein gene, and construct a model for relieving liver injury and endoplasmic reticulum stress and relieving hepatocyte necrosis. After knocking down the Afp gene, liver damage and increased intrahepatic endoplasmic reticulum stress of mice occur. After overexpression of Afp gene, liver damage and decreased intrahepatic endoplasmic reticulum stress of mice occur. The reduction of the protein level of AFP is proved to aggravate liver injury, which shows that the increase of AFP in liver is beneficial to alleviating liver injury, and the AFP can be applied to the preparation of the medicine for alleviating liver injury, protecting endoplasmic reticulum stress of liver or treating liver cancer.
After administration of WinRho ®SDF, a transitory increase of various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, C and E) and other blood group antibodies [for example, anti Duffy, anti Kidd (anti JKa) antibodies] 5may cause a positive direct or indirect (Coombs’) test. 

A large fetomaternal hemorrhage late in pregnancy or following delivery may cause a weak mixed field positive D utest result. Assess such an individual for a large fetomaternal hemorrhage and adjust the dose of WinRho ®SDF accordingly. The presence of passively administered anti Rh o(D) in maternal or fetal blood can lead to a positive direct Coombs’ test. If there is an uncertainty about the father’s Rh group or immune status, administer WinRho ®SDF to the mother.
Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.
INTRODUCTION: Chronic pancreatitis (CP) is a persistent, recurrent, and progressive disorder that is characterized by chronic inflammation and irreversible fibrosis of the pancreas. It is associated with severe morbidity, resulting in intense abdominal pain, diabetes, exocrine and endocrine dysfunction, and an increased risk of pancreatic cancer. The etiological factors are diverse and the major risk factors include smoking, chronic alcoholism, as well as other environmental and genetic factors. The treatment and management of CP is challenging, and no definitive curative therapy is currently available.
AREAS COVERED: This review paper aims to provide an overview of the different cell types in the pancreas that is known to mediate disease progression and outline potential novel therapeutic approaches and drug targets that may be effective in treating and managing CP. The information presented in this review was obtained by conducting a NCBI PubMed database search, using relevant keywords.
EXPERT OPINION: In recent years, there has been an increased interest in the development of novel therapeutics for CP. A collaborative multi-disciplinary approach coupled with a consistent funding for research can expedite progress of translating the findings from bench to bedside.
A oral care composition includes: (a) a guanidine active; (b) a film-forming polymer; (c) a hydrophobic viscosity modifier in an amount sufficient to provide the oral care composition with a particle settling time greater than 20 minutes; and (d) an oil carrier. The guanidine active is preferably L-arginine. The film-forming polymer is preferably GANTREZ. The hydrophobic viscosity modifier is preferably a gelled mineral oil. The oil carrier is preferably a vegetable oil. A method of cleaning teeth includes applying to the teeth the oral care composition such that the oral care composition cleans the teeth. A oral care implement includes: a handle; a head mounted to the handle, the head having an outer surface and a plurality of tooth cleaning elements extending outwardly from the outer surface; and a gelatin capsule containing the oral care composition positioned on the head.
Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
Biliary atresia (BA) is one of the most common cholestatic childhood diseases, with an estimated incidence of 1 in 8000-18,000 live births. BA is a progressive cholangiopathy with fibro-obliterative obstruction of the bile duct. The exact pathogenesis and etiology of BA have not been fully elucidated. The hypothesis that is most widely recognized states that injury to the biliary duct is caused by an initial infection and then an autoimmune response is induced by infection, leading to progressive damage to the biliary duct. Typical clinical manifestations of BA include persistent jaundice, acholic stools, and pigmented urine in the first months after birth. Unfortunately, the presentation time of the clinical features can be delayed in BA, which may lead to misdiagnosis. The average diagnostic age of BA is 60 days in many countries. Currently, effective management for BA is the Kasai portoenterostomy (KPE), which was originally reported by Morio Kasai in 1959. open Kasai portoenterostomy (OKPE) has been introduced to restore bile drainage for patients with BA and become the gold standard. Esteves et al. reported laparoscopic Kasai portoenterostomy (LKPE) for BA in 2002, but its efficacy remains controversial compared with OKPE. Several centers have revealed positive results with modified LKPE procedures. Nonetheless, LKPE is still a complex and challenging procedure with difficulties in fiber block dissection and anastomosis, resulting in a long learning curve. With merits of articulating wrists, 3D imaging field of vision and filter tremor, robotic surgery has been gradually applied to hepatobiliary disorders in children. Theoretically, robotic-assisted Kasai portoenterostomy (RAKPE) may overcome the difficulties of LKPE in fiber block dissection and anastomosis, thereby becoming a better option for BA. Currently, reports of RAKPE in infants with BA are limited to small case series, and its effectiveness remains controversial. However, there were no randomized controlled trials to verify its effectiveness. The objection was to compare the efficacy of Da Vinci robot-assisted with open Kasai portoenterostomy for biliary atresia.
For children in this group, the standard approach of the clinic will be applied first. The researcher will apply scales to the child before the procedure, the Child-Parent Information Form to the parents, and the child, parent and independent observer before and after the procedure. The patient's physiological parameters will be recorded by the nurse performing the procedure before, during and after the procedure. The device, which will be removed from the freezer just before the injection, will be placed by the researcher in contact with the skin, 3 to 5 cm above the injection site. Buzzy will be started 30-60 seconds before the process and will continue until the end of the process.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to nephrology, and can be used for recovery of peritoneal catheter drainage function. Method involves administering into the abdominal cavity through a peritoneal catheter a drug solution acting on tissues surrounding the lumen of the catheter. Drug solution used is mixture of 7.5% icodextrin in amount of 7-10 ml, in which a solution of alteplase 1.0-2.5 ml and atropine 0.5-1.0 ml are added. Obtained mixture is introduced into peritoneal catheter 2 to 7 times, after each introduction pulling the syringe piston without tension to obtain a solution. In the absence of preparing the solution, such administration of the mixture of solutions is repeated until obtaining a solution from the abdominal cavity, but no more than for 2 days. After preparing the solution from the abdominal cavity, mixture of 7.5% icodextrin in volume of 300-500 ml and a dexamethasone solution in amount of 2-4 ml, which is left in the abdominal cavity for 12-24 hours.EFFECT: use of the invention enables to significantly reduce the number of surgical interventions, several times reduce the number of bed days required for correction of dysfunction, thereby preventing the deterioration of quality of life and the state of patients and reducing the effectiveness of treating peritoneal dialysis.1 cl, 3 ex
The present invention relates to an external medicine for treating skin diseases, which belongs to a medicine for treating skin diseases. According to the design proposal provided by the present invention, the medicine is prepared from 93 to 95 wt. % of acetin, 2 to 3 wt. % of radix berberidis extract, 1.5 to 2 wt. % of scutellaria root extract and 1.5 to 2 wt. % of dandelion extract. The medicine has the characteristics of obvious therapeutic effect, convenient use, etc. when the medicine is used for treating skin diseases.
Cancer therapy-related cardiac dysfunction (CTRCD) is a complication of selected cancer therapy agents associated with decline in left ventricular ejection fraction (LVEF). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have established benefits in heart failure with reduced ejection fraction, but their efficacy for preventing CTRCD remains controversial. This narrative systematic review assessed the efficacy and safety of ACEI/ARB in the prevention of cancer therapy LVEF decline. We systematically searched PubMed, Embase and Cochrane from January 1980 to June 2022. Studies of interest were randomised controlled trials of patients with normal LVEF and active malignancy receiving cancer therapy, randomised to receive either an ACEI or ARB compared with a control group. The outcome was the change in LVEF from baseline to the end of the follow-up period. Death, clinical heart failure and adverse drug reactions were recorded. A total of 3731 search records were screened and 12 studies were included, comprising a total of 1645 participants. Nine studies assessed the prevention of anthracycline-induced LVEF decline, of which five showed a beneficial effect (1%-14% higher LVEF in treated groups), whereas four studies showed no effect. Three studies assessed the prevention of trastuzumab-induced LVEF decline, of which one showed a beneficial effect (4% higher LVEF) in a subset of participants. There are mixed data regarding the efficacy of ACEI/ARB in preventing the LVEF decline in patients undergoing anthracycline or trastuzumab therapy, with evidence suggesting no clinically meaningful benefit observed in recent studies.
In adults following a single administration of ZINGO the plasma levels of lidocaine were below the limit of detection (5 ng/mL). Signs of central nervous system (CNS) toxicity may start at plasma concentrations of lidocaine as low as 1000 ng/mL, and the risk of seizures generally increases with increasing plasma levels. Very high levels of lidocaine can cause respiratory arrest, coma, decreases in cardiac output, total peripheral resistance, and mean arterial pressure, ventricular arrhythmias, and cardiac arrest. The toxicity of coadministered local anesthetics is thought to be at least additive. In the absence of massive topical overdose or oral ingestion, other etiologies for the clinical effects or overdosage from other sources of lidocaine or other local anesthetics should be considered. The management of overdosage includes close monitoring, supportive care, and symptomatic treatment. Dialysis is of negligible value in the treatment of acute overdosage of lidocaine.
Alopecia areata (AA) is a major medical problem and is the most prevalent autoimmune disease in the US. AA represents the second most common form of hair loss and causes significant disfigurement and psychological distress to affected individuals. AA affects more individuals than most other autoimmune diseases combined, including lupus erythematosus, type 1 diabetes, psoriasis, multiple sclerosis and rheumatoid arthritis. In contrast to these conditions, research into the pathogenesis and the development of innovative therapies in AA has lagged behind.

Alopecia areata is a common form of hair loss which reportedly occurs in up to 1.7% of the population at some time in their life. Alopecia areata is apparently triggered when the individual's own immune system attacks hair follicles on the scalp or body resulting in hair loss ranging from single patches on the scalp (patch type alopecia areata) to loss of every hair on the scalp and body (alopecia universalis). Currently, there are limited treatment options for alopecia areata and unfortunately, the treatments utilized have never been rigorously tested in a placebo controlled trial.

Triamcinolone (Kenalog) is a steroid solution that has been used as a treatment for alopecia areata for over 50 years. It is administered via injection into the scalp and appears to have some efficacy for patients with mild to moderate alopecia areata. The investigators currently do not have objective data on the frequency of occurrence of successful regrowth, the duration of response or the incidence of side effects. Intralesional triamcinolone (IL TAC) is arguably the most commonly used treatments for AA, especially in patients with less than 50% hair loss. Despite this, there are no adequately powered, randomized controlled clinical trials (RCTs) examining the efficacy, safety, and duration of effect of IL TAC. In addition, the dosage or strength used varies among practitioners and the efficacy and safety of alternate doses of IL TAC has never been examined in a well designed RCT. Quantitative biomarkers for AA are a crucial step toward translational research aimed at clinical trials in AA.
Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
The invention relates to application of a compound oxymatrine to treating psoriasis, and relates to pharmaceutical acceptable form of the oxymatrine and application thereof to treating the psoriasis, and belongs to the field of medicines. The oxymatrine and the form can be used as injection, tablet, capsula, external emulsion and paste agent. The oxymatrine can combine the prior technology for treating the psoriasis such as ultraviolet ray irradiation. The compound oxymatrine can be applied to treating the psoriasis, and the amount of the oxymatrine is 100mg-1000mg. The psoriasis is ordinary psoriasis, erythroderma type psoriasis, pustule type psoriasis and arthrosis type psoriasis or complication caused by each type of psoriasis such as heart and cerebral vessel and metabolism diseases. The oxymatrine also can be applied to each tumour, dermatitis and eczema. The application of oxymatrine to treating psoriasis in the invention can reach an unexpected curative effect and a cure rate more than 80% compared with the prior medicine and drug for treating the psoriasis. This application is an innovation in treating the psoriasis.
BPH is a common urological pathology that affects 2480 per 100,000 men worldwide. With a rising population and increased age expectancy, the prevalence of benign prostatic hyperplasia (BPH) is increasing (Awedew et al. in Lancet Healthy Longev 3(11), 2022). There are many surgical management options for BPH with LUTS, including open simple prostatectomy (OSP), holmium laser enucleation of the prostate (HoLEP), transurethral resection of prostate (TURP), and transurethral electro vaporization of the prostate (TUVP) (Cho et al. in Int Neurourol J 24(1), 2020). However, these options often have a steep learning curve and increasing complexity with larger prostates. Robot-assisted simple prostatectomy (RASP) offers an alternative approach for large and very large glands for those already trained in robotic-assisted radical prostatectomy (RARP), particularly as robotic surgery continues to increase in popularity and is steadily becoming the standard of care in the management of prostate disease (Madersbacher et al. in Gerontology 65(5), 2019). The aim of this study was to demonstrate the surgical outcomes for men undergoing RASP for bothersome LUTs and/or acute urinary retention (AUR) secondary to BPH. A retrospective study was performed which included 105 patients who underwent RASP for the treatment of BPH causing lower urinary tract symptoms or acute urinary retention. This study reviews the pre-operative, (age, PSA, weight, prostate size) operative (duration, histology, estimated blood loss and hospital length of stay) and post-operative (duration of indwelling catheter, trial of void outcome, complications and post-operative PSA) outcomes, to evaluate the effectiveness of RASP for the management of BPH with LUTS. Data were analyzed using standard descriptive measures and multivariate logistic regression for comparison of continuous variables, significance was set to a CI of 95%. The median age of patients was 75 years (IQR 70-78) with a median prostate size of 135.5 cc (IQR 112.25-162.25). Patient demographic and pre-operative LUTS assessments are summarized in Table 1. Median operative time was 60 min (IQR 50-80), estimated blood loss was 350 ml (IQR 200-563), specimen weight was 98.5 g (IQR 69.5-120). Prostate size on imaging directly impacted operative duration (CI 0.07-0.2, p =  < 0.001). Eleven (10.5%) of the patients involved in the review had a post-operative complication, two (1.9%) considered major complications Clavien-Dindo grade ≥ 3. There was a statistically increased risk of complications associated with advanced age and prostate size (p = 0.043 and p = 0.001). This study, although limited by its retrospective nature, demonstrates the safety and utility of robotic simple prostatectomy in the context of large and very large prostate volumes. In particular, it offers a safe alternative for men with large prostates who otherwise may not be suitable for endoscopic management. Further prospective and randomized control trials are needed to reinforce the efficacy of RASP to assess its functional and cost effectiveness long term.
An electronic method and article of manufacture is provided for analyzing clinical trial budgets. A clinical trial budget is input into a processor. The budget includes activities and associated activity costs of a clinical trial. The activities of the inputted clinical trial budget are classified into a set of standardized service categories. The processor is used to electronically allocate the associated activity costs with the respective standardized service category so that budget costs of the clinical trial can be objectively analyzed. A report of the associated activity costs with the respective standardized service category is outputted for use in analyzing budgets for clinical trials.